Meeting Process Sample Clauses

Meeting Process. (a) A quorum exists when a minimum of fifty percent (50%) of JHSC Members of each Worker and Employer representatives are present for the meeting. (b) Meetings will be held monthly in accordance with the yearly schedule. (c) All JHSC Members will be provided time off work, one (1) hour once (1) per month, to prepare health and safety issues prior to the monthly meeting. Any additional time and loss of earnings and premiums required to perform their duties and responsibilities, as JHSC members, will be provided as necessary and approved by the Employer. Permission to take time off work to discuss health and safety issues prior to the monthly meeting will be granted at the discretion of the Employer but will not be unreasonably denied. (d) New business will be placed on the agenda and prioritized by the committee. (e) The JHSC will endeavour to build consensus in their decision making process. (f) All JHSC recommendations will be presented to the Employer. (g) Non JHSC union or non-union persons working at the Fairmont Royal York hotel, on their own time, may attend any of the monthly JHSC meetings with prior approval of both co-chairs, and said approval shall not be unreasonably denied. An approval is required, from both co-chairs, prior to a non- employee of the Fairmont Royal York hotel attending a JHSC meeting, and said approval shall not be unreasonably denied. (h) Minutes of the meeting will be documented and copies supplied to each JHSC member (i) The following items shall be reviewed at each meeting: · Agenda items · Old business (including recommendations) · New business · Workplace inspection results · Incident/accident reports · Other reports.
Sample 1Sample 2Sample 3See All (8)
AutoNDA by SimpleDocs
Meeting Process. (a) A meeting held under this clause 9.5 must be held at a time and place (as determined by Aurizon Network acting reasonably) in Brisbane on a Business Day during normal business hours not less than 10 Business Days, and not more than 15 Business Days, after the date that Aurizon Network gives the Study Funder a meeting invitation. (b) At the meeting, the Study Funder, the Other Study Funders and Aurizon Network must agree in writing upon: (i) whether the Study Funder and/or one of more of the Other Study Funders (Continuing Study Funders) continue to fund and Aurizon Network will continue carrying out the Rail Study; and (ii) any necessary amendments to vary: (A) in the case of the Study Funder, the Study Funder’s Study Commitment; and (B) in the case of any Other Study Funder, its “Study Funder’s Study Commitment” (as defined in its Other Funding Agreements), so that, in aggregate, the Continuing Study Funders are obliged to fund, in addition to their Initial Commitments, at least 115% of the Funding Shortfall on the terms of, subject to clause 9.5(b)(iii), this Agreement and/or their Other Funding Agreements (as applicable); (iii) agree in writing to any consequential variations to this Agreement and/or their Other Funding Agreements (as applicable) required, including as a consequence of the Continuing Study Funders being obliged to fund, in addition to their Initial Commitments, at least 115% of the Funding Shortfall; and (iv) provide Aurizon Network with additional Bank Guarantees that, in aggregate, equal at least 115% of the Funding Shortfall. (c) If clause 9.5 applies but the Study Funder is not a Continuing Study Funder, then this Agreement will automatically terminate without the need for either Party to give notice of termination to the other Party on the date that the sum of: (i) the Loaned Amount; and (ii) any amounts which are due for payment, but not yet paid, by the Study Funder under a Drawdown Notice given by Aurizon Network, equals the maximum aggregate amount that the Study Funder is obliged to lend to Aurizon Network under this Agreement. (d) If clause 9.5 applies but the Study Funder and all Other Study Funders are not Continuing Study Funders, then Aurizon Network: (i) will have no obligation to continue to carry out, or to procure the carrying out of, the Rail Study; and (ii) the Study Funder and each Other Study Funder will be taken to have jointly given Aurizon Network a notice of termination under clause 17.1(a).
Sample 1Sample 2Sample 3See All (4)
Meeting Process. The MRC meetings will proceed in the following manner: Public comment period. Establish quorum. Review and approve agenda. Presentation, discussion, decision, and standing agenda items. New business. Action item review. Tentative agenda items for future meetings.
Sample 1
Meeting Process. The Co-Chairs shall facilitate meetings using a process which gives all members opportunity to be heard, such as a collaborative circle process (peacemaking process). The CAC may employ any decision-making process it desires, as long as it is clear for the record when a matter is up for decision, what the official CAC action is on the matter, and the manner of adoption (i.e. consensus or vote). Decision process shall have the goal of achieving consensus if possible and practicable. If
Sample 1
Meeting Process. Annual meetings of the AMPT and regularly scheduled AMTT meetings will be formally announced to all Parties, the BCWC, CALFED, and any person requesting such notification.97 Chairpersons of the AMPT and AMTT will provide certified notice of regularly scheduled meetings at least one month in advance to Party representatives of their respective team and representatives of the BCWC, CALFED, and any person requesting such notification.97 Members of each team then have one week to respond with suggestions for the meeting agenda, which will be circulated by the Chairperson to representatives of each Party and representatives of the BCWC, CALFED, and any person requesting such notification.97 The annual AMPT meeting and ad hoc meetings of the AMPT that are not scheduled in direct response to an emergency will be formally announced to the public. The scheduled meeting location and time and the meeting agenda will be published a minimum of three times, at least two weeks before scheduled meetings, in major newspapers or other Contemporary standard media in Shasta and Tehama Counties. Interested persons may attend any meeting, contribute to discussions, and provide suggestions regarding implementation of the AMP.98 At least one representative from each of the Parties will be required to attend regularly scheduled and ad-hoc meetings announced according to the aforementioned process or to provide a proxy. A proxy may be transmitted electronically if followed by a document meeting Contemporary formal documentation standards adopted by the AMPT. To ensure that absenteeism does not impede the decision-making process, if a Party or Parties is not represented in person or by proxy at regularly scheduled and ad-hoc meetings announced according to the aforementioned process, and unless a written proxy from the absent party conforming to Contemporary formal documentation standards is received by the Chairperson of the meeting within two weeks, then the dispute resolution process will be triggered. The Chairs of the AMPT and AMTT will be held by a representative of one of the Parties. Each Chair will rotate annually among the four Parties such that no Party will be the Chair of one team more than once in any four-year period. Furthermore, the Chair for the AMTT will always represent a different Party than the Chair for the AMPT so that the Chairpersons of the AMTT and the AMPT are never representatives of the same Party at any given time.99 A Chairperson-elect will be appoint...
Sample 1
Meeting Process. A quorum exists when a minimum of fifty percent (50%) of Members of each Union and Company representatives are present for the meeting. Meetings will be held monthly in accordance with the yearly schedule. All Members will be provided time off work, one (1) hour once (1) per month, to discuss health and safety issues prior to the monthly meeting. Any additional time and loss of earnings and premiums required to perform their duties and responsibilities, as members, will be provided as necessary and approved by the Company. Permission to do so shall not be unreasonably denied. New business will be placed on the agenda and prioritized by the committee. The will endeavour to build consensus in their decision making process. All recommendations will be presented to the Company. Non union or non-union persons working at the Fairmont Royal York hotel, on their own time, may attend any of the monthly meetings with prior approval of both co-chairs, and said approval shall not be unreasonably denied. An approval is required, from both co-chairs, prior to a non- employee of the Fairmont Royal York hotel attending a meeting, and said approval shall not be unreasonably denied. Minutes of the meeting will be documented and copies supplied to each member The following items shall be reviewed at each meeting: Agenda items Old business (including recommendations) New business Workplace inspection results reports Other reports.
Sample 1
Meeting Process. The Executive Board members shall designate a Chair who shall conduct meetings in accordance with Robert’s Rules of Order. Votes shall be open to the Executive Board members and recorded by the Secretary. Prior to each meeting, the Chair shall set an agenda and cause it to be circulated to the Executive Board members no fewer than ten days prior to a regularly scheduled meeting, and three days prior to a specially called meeting. All meetings of the Executive Board shall be held at a time and place that is accessible to the public, to the extent consistent with Section 6.4.
Sample 1
AutoNDA by SimpleDocs
Meeting Process. The meetings shall comply with any applicable law. Meetings require attendance of one- half of the voting membership to be considered a quorum. The meeting minutes will record the following: 1) Members present, 2) Motions, proposals and their dispositions, 3) Results of all votes and the vote of each member by name and the organization that they are representing; 4) The substance of any discussion on any matter; and 5) A reference to any document discussed at the meeting. The forgoing shall not apply to discussions pertaining to changes to collective bargaining agreements.
Sample 1
Meeting Process 
Sample 1

Related to Meeting Process

  • Meeting Rooms In accordance with Hospital policy, the Union may use designated meeting rooms of the Employer for meetings of the Local Unit, provided sufficient advance request for meeting facilities is made to the Director, Employee and Labor Relations, or designee, and space is available.

  • Meeting Schedule Committees shall meet when necessary, but not more than once each calendar quarter, unless mutually agreed otherwise.

  • Protocol The attached Protocol shall be an integral part of this Agreement.

  • Meeting Minutes The Secretary of the Council (or the Secretary’s designee) shall be responsible for the minutes of each meeting of the Members and such meeting minutes will be provided to the public no later than thirty (30) days after such meeting minutes are accepted by a majority of the Members.

  • Meeting Space Union representatives may request the use of state property to hold union meetings. Upon prior notification, the Employer will provide meeting spaces where feasible. Such meetings will not interrupt state work and will not involve employees who are working. The Employer shall make space available for Union representatives to have confidential discussions with employees on an as needed basis subject to availability.

  • Meeting Attendance The Contractor shall attend such meetings of the Town relative to the Scope of Work set forth in Exhibit A as may be requested by the Town. Any requirement made by the named representatives of the Town shall be given with reasonable notice to the Contractor so that a representative may attend.

  • Signaling protocol The Parties will interconnect their networks using SS7 signaling where Technically Feasible and available as defined in GR 905 Telcordia Standards including ISDN User Part (ISUP) for trunk signaling and TCAP for CCS-based features in the Interconnection of their networks. All Network Operations Forum (NOF) adopted standards shall be adhered to. Where available, CenturyLink signaling services to link its Signaling Transfer Points (STPs) for CLEC switches which connect to CenturyLink’s STPs via “A” links or for CLEC’s STPs to connect to CenturyLink’s STPs via “D” links which are dedicated to the transport of signaling for local Interconnection, may be ordered from the CenturyLink Tariff.

  • For Closed Meeting Minutes Prepares written closed meeting minutes that include: The date, time, and place of the closed meeting The Board members present and absent A summary of discussion on all matters proposed or discussed The time the closed meeting was adjourned Upon request of a Board member: 1. Provides access to the closed session minutes at a reasonable time and place without disrupting District operations; 2. Supervises the access to the closed session minutes or delegates it to one of the following individuals in the District: a. The Recording Secretary, b. The Superintendent or designated administrator, or c. Any elected Board member; and 3. Logs the access in 2:220-E7, Access to Closed Meeting Minutes and Verbatim Recordings.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!